Phase 1 Parkinson’s Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated

Overview of attention for article published in Neurology and Therapy, October 2018

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 5 X users

Citations

dimensions_citation: 33 Dimensions

Readers on

mendeley: 32 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 33 publications that cite this research output.

33

The most recent citing publications are shown below. View all 33 publications that cite this research output on Dimensions.

Functionally selective dopamine D1 receptor endocytosis and signaling by catechol and non-catechol agonists

Preprint in bioRxiv (April 2024)

Dopamine D1–D5 Receptors in Brain Nuclei: Implications for Health and Disease

Article in Receptors (April 2024)

Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson’s Disease

Article in CNS & Neurological Disorders - Drug Targets (January 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.